Prognoza
Średnia cena docelowa analityków wynosi 104,97 € (+16,30%). Mediana wynosi 107,44 € (+19,03%).
| Kupuj |
5 |
| Trzymaj |
4 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
GRAIL surges after positive FDA review and advisory panel recommendation
On September 21 the FDA published a positive assessment report on the multi-cancer early detection test Galleri, and an independent expert panel on September 24 voted largely in favor of approval. The news sparked a roughly 34% one-day rise in GRAIL’s stock. Despite a quarterly loss of about $110 million on $44.7 million in revenue, the company has more than $860 million in cash and is targeting a market launch in 2027. » Więcej na finanzen.net
GRAIL sees FDA approval and reimbursement as key hurdles for Galleri
At the Morgan Stanley Healthcare Conference, GRAIL said that clinical evidence, FDA approval and reimbursement together are prerequisites for broad commercial adoption of the Galleri blood test. Test volume recently rose 35% year‑over‑year; the company reports a positive predictive value of over 60%, specificity of over 99.5% and an accuracy of signal‑origin determination of over 90%. The PMA submission relies on PATHFINDER‑2 and NHS data; FDA approval is expected to ease discussions with payers and an NCD with CMS. GRAIL highlights operational improvements (integration with Epic/athenahealth, partnership with Quest) and international expansion plans, but sees reimbursement as the "end goal" for broad market access. » Więcej na de.investing.com
FDA advisory panel to review GRAIL's blood test Galleri on 23 September
An FDA advisory panel (Molecular and Clinical Genetics Panel) will decide on 23 September on the PMA approval application for GRAIL's Galleri blood test. The test detects cancer-specific methylation patterns and is intended to complement guideline-based screening. The approval application relies on data from 25,490 participants in the PATHFINDER-2 study and more than 70,000 participants from the intervention arm of the NHS-Galleri study; Galleri was granted Breakthrough Device status in 2018. » Więcej na de.investing.com
Grail's Galleri edges closer to approval as follow-up data and subgroup results strengthen case
Grail missed the NHS trial's primary endpoint for reducing Stage III–IV cancers but management says 12‑month follow-up could reveal late‑stage cancers in the control arm and improve the trial's signal. A pre‑specified group of 12 deadly cancers showed a favorable trend and episode sensitivity substantially higher than overall results, while positive predictive values (52% NHS, 60.3% PATHFINDER 2) bolster the test's economic case. FDA clearance and insurer cost‑benefit analyses remain decisive for real‑world adoption and the stock's upside, leaving the situation attractive mainly to risk‑seeking investors. » Więcej na finance.yahoo.com
Grail poised to benefit from positive Galleri trial results and potential FDA approval
Grail's Galleri multi-cancer early detection test showed favorable results in two major studies (NHS Galleri 2 and Pathfinder 2) presented at ASCO 2026, including reductions in late-stage diagnoses and increased early-stage detections. Grail submitted Galleri for FDA approval in January 2026 and Medicare coverage for FDA-approved MCED tests was enabled by recent legislation, which could accelerate insurer reimbursement. The company remains unprofitable and faces competition from Exact Sciences/Abbott and Guardant Health, so investor gains depend on regulatory approval and payer uptake. » Więcej na finance.yahoo.com
Dane finansowe
W ostatnim kwartale GRAIL INC. DL-,01 Aktie osiągnęła przychody w wysokości 33,14 mln € i zysk netto w wysokości -91,44 mln €
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 33,14 mln | 7,44% |
| Zysk brutto | -15,99 mln | 36,63% |
| Zysk netto | -91,44 mln | 20,59% |
| EBITDA | -87,27 mln | 28,44% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 4,29 mld € |
Liczba akcji | 44,96 mln |
Maksimum/minimum z 52 tygodni | 151,58 € - 37,79 € |
| Dywidendy | Nie |
Beta | 3,25 |
C/Z (PE Ratio) | -11,04 |
PEG (PEG Ratio) | -0,52 |
C/WK (PB Ratio) | 2,00 |
C/S (PS Ratio) | 28,29 |
Profil spółki
GRAIL, Inc., spółka biotechnologiczna, koncentruje się na opracowywaniu technologii do wczesnego wykrywania raka. Firma rozwija Galleri, test przesiewowy dla osób bezobjawowych powyżej 50. roku życia, oraz DAC, narzędzie wspomagające diagnostykę nowotworów, którego celem jest przyspieszenie ustalenia diagnozy u pacjentów, u których istnieje kliniczne podejrzenie raka. Spółka prowadzi również prace nad testami minimalnej resztkowej choroby (MRD) i innymi testami stosowanymi po diagnozie. Firma została założona w 2015 roku i ma siedzibę w Menlo Park w Kalifornii. GRAIL, Inc. działa jako była spółka zależna Illumina, Inc.
| Nazwa | GRAIL INC. DL-,01 Aktie |
| CEO | Joshua J. Ofman |
| Siedziba | Sunnyvale,
ca Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Ochrona zdrowia |
| Branża | Biotechnologia |
| Debiut giełdowy | 01.06.2018 |
| Pracownicy | 910 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
Düsseldorf | NL0.DU |
München | NL0.MU |
Frankfurt | NL0.F |
NASDAQ | GRAL |